RGNX Quote, Financials, Valuation and Earnings

PTC Therapeutics has a net margin of -241.28% compared to Regenxbio's net margin of -30.91%. Regenxbio's return on equity of -70.45% beat PTC Therapeutics's return on equity of --.

Regenxbio has a consensus price target of $32.50, signalling upside risk potential of 255.19%. On the other hand PTC Therapeutics has an analysts' consensus of $64.64 which suggests that it could grow by 30.51%. Given that Regenxbio has higher upside potential than PTC Therapeutics, analysts believe Regenxbio is more attractive than PTC Therapeutics.

Regenxbio has a beta of 1.263, which suggesting that the stock is 26.294% more volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.577, suggesting its less volatile than the S&P 500 by 42.34%.

Regenxbio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regenxbio pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.

Regenxbio quarterly revenues are $21.2M, which are smaller than PTC Therapeutics quarterly revenues of $213.2M. Regenxbio's net income of -$51.2M is higher than PTC Therapeutics's net income of -$65.9M. Notably, Regenxbio's price-to-earnings ratio is -- while PTC Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regenxbio is 5.44x versus 4.72x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -241.28% compared to Regenxbio's net margin of 24.22%. Regenxbio's return on equity of -70.45% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Regenxbio has a consensus price target of $32.50, signalling upside risk potential of 255.19%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $850.21 which suggests that it could grow by 41.08%. Given that Regenxbio has higher upside potential than Regeneron Pharmaceuticals, analysts believe Regenxbio is more attractive than Regeneron Pharmaceuticals.

Regenxbio has a beta of 1.263, which suggesting that the stock is 26.294% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.437, suggesting its less volatile than the S&P 500 by 56.337%.

Regenxbio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.15% to investors and pays a quarterly dividend of $0.88 per share. Regenxbio pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Regenxbio quarterly revenues are $21.2M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Regenxbio's net income of -$51.2M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Regenxbio's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 15.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regenxbio is 5.44x versus 4.88x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -241.28% compared to Regenxbio's net margin of 24.16%. Regenxbio's return on equity of -70.45% beat Sarepta Therapeutics's return on equity of 20.83%.

Regenxbio has a consensus price target of $32.50, signalling upside risk potential of 255.19%. On the other hand Sarepta Therapeutics has an analysts' consensus of $147.33 which suggests that it could grow by 143.77%. Given that Regenxbio has higher upside potential than Sarepta Therapeutics, analysts believe Regenxbio is more attractive than Sarepta Therapeutics.

Regenxbio has a beta of 1.263, which suggesting that the stock is 26.294% more volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.930, suggesting its less volatile than the S&P 500 by 6.993%.

Regenxbio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regenxbio pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Regenxbio quarterly revenues are $21.2M, which are smaller than Sarepta Therapeutics quarterly revenues of $658.4M. Regenxbio's net income of -$51.2M is lower than Sarepta Therapeutics's net income of $159M. Notably, Regenxbio's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 26.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regenxbio is 5.44x versus 3.54x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -241.28% compared to Regenxbio's net margin of 31.35%. Regenxbio's return on equity of -70.45% beat Vertex Pharmaceuticals's return on equity of -3.23%.

Regenxbio has a consensus price target of $32.50, signalling upside risk potential of 255.19%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.32 which suggests that it could grow by 1.31%. Given that Regenxbio has higher upside potential than Vertex Pharmaceuticals, analysts believe Regenxbio is more attractive than Vertex Pharmaceuticals.

Regenxbio has a beta of 1.263, which suggesting that the stock is 26.294% more volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.617%.

Regenxbio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regenxbio pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Regenxbio quarterly revenues are $21.2M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. Regenxbio's net income of -$51.2M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, Regenxbio's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regenxbio is 5.44x versus 11.62x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.